Skip to content
Companies

Synlico

Engineered T cell therapies for solid tumors

Raised to date

$3M

of $3M offered across 1 Form D filing

Investors
1
Last filed
Feb 25, 2025

About

Synlico Inc. is an AI-powered drug discovery company dedicated to transforming traditional approaches in oncology through the development of engineered T cell therapies tailored to combat solid tumors. By harnessing advanced computational techniques, Synlico leads a paradigm shift in understanding and addressing the complexities of cellular behavior in the tumor microenvironment.

Synlico stands out for its innovative integration of causality into drug design, enabling the engineering of therapies that are both more effective and tailored to the unique characteristics of individual patients' tumors.

Funding

  • EquityFiled Feb 25, 2025Form D
    $3M/ $3M

Product

CausalCell AI

Oncology / Drug Discovery

CausalCell AI is a computational technology platform that utilizes single-cell bioinformatics combined with machine learning and causal discovery methodologies. This advanced platform provides invaluable insights into the tumor microenvironment, enhancing the ability to develop targeted T cell therapies.

  • Detailed analysis of tumor microenvironment heterogeneity
  • Patient reclassification based on shared tumor microenvironment signatures
  • Identification of causal relationships between T cell intracellular elements and their functional outcomes in patients

Built for

Healthcare industry, particularly oncology research and therapeutics

People on file